In breast cancer patients, the onset of subclinical tumor cell spread is the putative precursor stage of solid metastases and can be assessed with the detection of disseminated tumor cells (DTC) in bone marrow samples or circulating tumor cells (CTC) in the blood by immunocytochemical and molecular techniques. Sequential peripheral blood analyses should be more acceptable than bone marrow aspirations and many research groups are currently assessing CTC with different methods. In patients with no clinical signs of overt metastases, detection rates range from 10 to 100% [1], (Table 1). The detection of CTC is of potential clinical relevance in the context of a growing number of therapeutic options, especially in the adjuvant setting when no tumor is present. In contrast to patients with metastatic disease, less information about the prognostic relevance of CTC in the blood of patients with earlystage disease is available [2]. In this context, the study published by Apostolaki and coworkers in this issue of Breast Cancer Research and Treatment is of importance [3]. The authors use a nested RT-PCR assay for HER2 mRNA to detect CTC in patients with primary breast cancer after surgery and before the start of systemic treatment. With this method, they detect CTC in 24.5% of 216 patients. The detection of a positive mRNA signal for HER2 is an independent prognostic factor for disease free and overall survival. No correlation of CTC detection by HER2 mRNA and HER2 status of the primary tumors was observed. In metastatic patients, it has been demonstrated that patients with HER2 negative primary tumors show HER2 positive CTC. Moreover, a subset of these patients were treated with trastuzumab and showed clinical response [4, 5]. Since the number of patients included in these studies were small, no conclusive data have been obtained. The intriguing perspective of this study is on one hand the potential clinical impact since HER2 is a prominent therapeutic target in breast cancer and on the other hand the biologic hypothesis supported by this study: HER2-positive cells are more frequently disseminated from the primary tumors. When looking at the seemingly high frequency of HER-positive CTC here one has to bear in mind that HER2 is usually not overexpressed or amplified in all cells of a primary tumor, even in those tested as ‘‘positive’’. In addition, the applied RNA-based test is not able to detect a heterogeneity in HER2 expression between different CTC (i.e., the concomitant presence of HER2-positive and HER2-negative CTC in one sample), which was, however, observed by the authors of this study when performing a immunocytochemical or FISH analysis in a small subset of patients tested HER2 positive by RNA.
Read full abstract